Cartesian Therapeutics, Inc. Cybersecurity Tracker

Cybersecurity Tracker for Cartesian Therapeutics, Inc. including cybersecurity governance, scorecard, incidents and more.

Cybersecurity Governance

Filing Date Source
2026-03-09 SEC 10-K
2025-03-13 SEC 10-K
2024-03-07 SEC 10-K

Cybersecurity Incidents

No incidents found.

Regulatory Actions Coming Soon

SEC enforcement actions, FTC orders, and state regulatory proceedings coming soon.

Litigation Coming Soon

Cybersecurity-related lawsuits, class actions, and settlements coming soon.

Corporate Governance Coming Soon

Board directors, committees, and auditor details coming soon.

Company

Profile

Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company developing autologous mRNA cell therapies (mRNA CAR-T) to treat autoimmune diseases, supported by a proprietary technology and in-house cGMP manufacturing platform (lead candidates include Descartes-08 and Descartes-15).

Name Cartesian Therapeutics, Inc.
Headquarters Massachusetts; U.S.A
Employees 66
Revenue $38.91M
Industry Biotechnology
Sector Healthcare
Ticker RNAC
CIK 1453687
Website http://www.selectabio.com
Category Non-accelerated Filer
Fiscal Year End December 31

Relationships

No known relationships.